Our Pipelines
Our Pipelines
ALL 5 proven human vaccine technology platforms, each with at least one vaccine product commercialized or in
development
Viral vaccines
Rabies
Serum-free Rabies Vaccine Globally first-in-class
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Iterative-process Highly-effective HDC Rabies Vaccine In-house R&D
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Influenza
Quadrivalent Influenza Virus Vaccine (MDCK Cells) Domestically first-in-class
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
HFMD
EV71-CA16 HFMD Vaccine (HDC) Globally first-in-class
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
mRNA vaccines
Rabies
Iterative mRNA Rabies Vaccine Globally first-in-class
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Shingles
mRNA Shingles Vaccine Domestically first-in-class IND approval (in China & US)
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
RSV
mRNA RSV Vaccine Domestically first-in-class IND approval (in China & US)
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Influenza
mRNA Influenza Vaccine Globally first-in-class
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Bacterial vaccines
Pneumonia
13-valent pneumococcal vaccine (PCV13) In-house R&D
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
20-Valent Pneumococcal Conjugate Vaccine (PCV20) Domestically first-in-class
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
24-Valent Pneumococcal Conjugate Vaccine (PCV24) Globally first-in-class
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) In-house R&D
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Meningococcal
Group ACYW135 Meningococcal Conjugate Vaccine (MCV4) In-house R&D
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Hexavalent Meningococcal Vaccine Globally first-in-class
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Group B Strp
Hexavalent Group B Streptococcus Conjugate Vaccine Globally first-in-class
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Tetanus
Absorbed Tetanus Vaccine In-house R&D
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Hib
Hib Conjugate Vaccine In-house R&D
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Combination vaccines
DTcP-Hib-Mcv4 In-house R&D
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Diphtheria, tetanus and pertussis (acellular, components) vaccine (DTcP) In-house R&D
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
Genetically engineered vaccines
Genetically engineered vaccine
Recombinant Group B Meningococcal Vaccine In-house R&D
Progress:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approval
√
AI is being used to design the antigen structure and mRNA sequence of vaccines, and we’re also trying to use
AI to
assist in vaccine process R&D. In the future, we expect to increase the depth of existing applications
and expand its
application in clinical trial data analysis.
